Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

The overall five-year survival rate for people with active multiple myeloma in the United States has increased steadily over time, to more than 62% today. It’s important to remember that even the most ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.

The company previously teased the overall survival (OS ... of relapsed or refractory multiple myeloma." The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm ...